跳至主要内容
临床试验/NCT07479602
NCT07479602尚未招募4 期

Impact of Intranasal Dexmedetomidine-esketamine Administration on Postoperative Pain in Pediatric Patients Undergoing Adenotonsillectomy: a Randomized, Placebo-controlled Trial

Peking University First Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2026年4月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
尚未招募
入组人数
160
试验地点
1
主要终点
Area under curve of pain intensity within 48 hours after surgery

研究概览

简要总结

Postoperative pain after adenoid and tonsil surgery is significant, with approximately 75% of pediatric patients experiencing severe postoperative pain. Currently, there is a lack of clinical strategies to safely and effectively manage postoperative pain in children undergoing adenoid and tonsil surgery. Dexmedetomidine and esketamine can achieve appropriate sedation levels and alleviate postoperative pain when used in children. Both drugs can be administered intranasally, and their pharmacological effects complement each other, reducing side effects. This study aims to investigate whether intranasal administration of dexmedetomidine-esketamine combination can improve postoperative analgesia in children undergoing adenoid and tonsil surgery.

详细描述

Adenoid and tonsil surgery is a common surgical intervention for obstructive sleep-disordered breathing and is one of the most frequently performed surgeries in pediatric patients. The operation lasts approximately 45 minutes but is associated with significant postoperative pain; about 75% of children experiencing severe postoperative pain, which can affect swallowing and may cause psychological distress in children. About 12-16% of children return to hospital after discharge due to pain or dehydration. Postoperative analgesia during the initial two days is often inadequate. Currently, clinicians have explored various strategies to effectively manage postoperative pain after adenoid and tonsil surgery in children, but the results are unreliable and have multiple side effects.

Dexmedetomidine is a highly selective α2 receptor agonist with anxiolytic, sedative, and analgesic effects, and has a minimal impact on respiration at low doses. When used as an adjuvant analgesic after surgery, it improves analgesia, reduces opioid consumption, and decreases opioid-related adverse events. Dexmdetomidine is also used in pediatric patients but may produce bradycardia and hypotension at routine doses. Ketamine is a non-competitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist and has been used as an anesthetic and analgesic for decades. Esketamine is the S-enantiomer of ketamine and has an analgesic potent of approximately 2 times of that of ketamine. Esketamine is also used in children but may produce neuropsychiatric side effects.

Dexmedetomidine and esketamine can each be administered intranasally. When used in combination, the sympathomimetic activity of esketamine may counteract the bradycardic and hypotensive effects of dexmedetomidine, and the sedative effect of dexmedetomidine can mitigate the neuropstchiatric side effects of esketamine. Intranasal administration of dexmedetomidine-esketamine combination has been used for preoperative sedation in children and may improve postoperative analgesia after adenoid and tonsil surgery. However, the success rate and efficacy of intranasal dexmedetomidine-esketamine are difficult to guarantee in preschool children due to poor cooperation and intranasal secretions.

This randomized trial is designed to test the hypothesis that intranasal administration of dexmedetomidine-esketamine combination after anesthesia intubation may improve postoperative analgesia in children undergoing adenoid and tonsil surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
3 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Aged 3-7 years old.
  • Scheduled to undergo adenoidectomy and/or tonsillectomy under general anesthesia.
  • Provides written informed consent by the guardian.

排除标准

  • Unsuitable for intranasal administration due to nasal diseases (such as rhinitis, nasal polyps, or any condition causing nasal congestion).
  • Clearly diagnosed cardiovascular and respiratory diseases.
  • Communication barriers due to delayed neurological development or visual or hearing impairments.
  • Traumatic brain injury or neurosurgery.
  • Abnormal liver and kidney function (biomarkers higher than twice of the upper normal limits).
  • Amercian Society of Anesthesiologists classification ≥ III.
  • Body mass index higher than the 95th percentile of the age- and sex-standardized references.
  • Allergic to dexmedetomidine and/or esketamine.
  • Any other conditions that are deemed unsuitable for study participation.

研究组 & 干预措施

Intervention group

Experimental

Dexmedetomidine-esketamine combination will be administered intranasally after anesthesia induction.

干预措施: Intranasal dexmedetomidine-esketamine (Drug)

Control group

Placebo Comparator

Placebo (normal saline) will be administered intranasally after anesthesia induction.

干预措施: Intranasal placebo (normal saline) (Drug)

结局指标

主要结局

Area under curve of pain intensity within 48 hours after surgery

时间窗: Up to 48 hours after surgery

Pain intensity will be assessed with the Face, Legs, Activity, Cry, Consolability scale (FLACC; scores range from 0 to 10, with higher scores indicating more severe pain intensity) at 10, 20, an 30 minutes after entering the post-anesthesia care unit (PACU), at 3 and 6 hours after surgery, and then twice daily (8:00-10:00 am, 6:00-8:00 pm) until 48 hours after surgery.

次要结局

  • Sleep quality during the first three nights after surgery(Up to three days after surgery)
  • Cumulative consumption of analgesics within 48 hours(Up to 48 hours after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dong-Xin Wang

Chief Physician, Professor

Peking University First Hospital

研究点 (1)

Loading locations...

相似试验